Income Statement Presentation 2023

Polivy in 1L DLBCL: First new treatment in >20 years Included in NCCN guideline as category 1*; NICE reimbursement obtained** Ph III (POLARIX) results PFS strongly predicts OS outcomes¹ 100 80 PFS (%) P40 60- 20 3-year APFS: 7.7% HR 0.76 95% CI: 0.60-0.97 0 0 No. of patients at risk Pola-R-CHP R-CHOP PFS Pola-R-CHP (N=440) R-CHOP (N=439) + Censored 12 24 36 48 55 Time (months) 440 439 405 390 354 331 331 300 313 284 242 222 103 94 66 0 0 59 2 1 ASH 2022 A 0.31 n = 25 0.2- r = 0.772 Log HR (OS) 0.1- 0- -0.1- -0.2- -0.3- -0.4+ T -0.4 -0.3 -0.2 -0.1 0 0.1 Log HR (PFS) 0.2 • Updated Ph III (POLARIX) results: median follow-up 39.7 months demonstrated sustained PFS benefit in Pola-R-CHP (HR 0.76) vs. R-CHOP • PFS is a valid endpoint recognized by all major health authorities to demonstrate efficacy benefit in 1L DLBCL • • Polivy in 1L DLBCL has significant potential to decrease cost for progressive disease, due to fewer patients progressing Approved in EU/UK/Japan/China/Canada, overall >50 countries; US filing: ODAC on Mar 9th and PDUFA date set for Apr 2nd Roche POLIVYⓇ polatuzumab vedotin Polivy in collaboration with Seagen; *NCCN guidelines for B-Cell Lymphomas (V1.2023); **NICE: Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma [ID3901]; 1 Shi Q, Schmitz N, Ou FS, et al. Progression free survival as a surrogate end point for overall survival in first line diffuse large B cell lymphoma: An individual patient level analysis of multiple randomized trials (SEAL). J Clin Oncol.2018;36(25):2593 2602; DLBCL-diffuse large B-cell lymphoma; PFS=progression free survival; OS-overall survival; R-CH(O)P=Rituxan + cyclophosphamide + doxorubicin + (vincristine) + prednisone; HR-hazard ratio; NCCN=national comprehensive cancer network; NICE=national institute for health and care excellence 24 24

View entire presentation